ResMed CEO Sells Shares Following Fiscal First-Quarter Earnings Beat

ResMed Inc. Chief Executive Officer Michael Farrell sold 4,993 shares of company stock on Monday, November 9th. Disclosed in an SEC regulatory filing, the transactions occurred at an average price of $235.35 per share, generating $1,175,102.55 in total proceeds. The trade, carried out via a pre-scheduled Rule 10b5-1 arrangement, trimmed Farrell's stake by 1.03% and left him directly holding 479,803 shares valued at $112,921,636.05.

The insider transaction followed ResMed's first-quarter fiscal 2027 update announced on Thursday, October 29th. The medical equipment designer reported adjusted earnings per share of $2.91, up from $2.55 during the matching quarter last year. The outcome surpassed the consensus expectation of $2.67 by $0.24. Total quarterly revenue increased 5.9% year over year to $1.41 billion, ahead of the $1.39 billion anticipated by analysts.

A sustained appetite for core sleep equipment supported the top-line performance. Revenue across the Sleep and Breathing Health division climbed approximately 8% to $1.26 billion, driven by an 8% gain in Americas sleep devices to $436 million and a 10% rise in total masks and other accessories to $540 million. In contrast, Residential Care Software sales slipped about 7% to $155 million after ResMed completed the sale of its MatrixCare business on September 1, 2026. Adjusted gross margin rose 50 basis points to 62.5% as manufacturing and distribution efficiencies cushioned against foreign exchange pressure.

In addition to quarterly figures, ResMed scheduled a quarterly dividend of $0.66 per share, set for distribution on Thursday, December 17th to shareholders of record on Thursday, November 12th. This dividend level equates to $2.64 annually and an annualized yield of 1.1%, against a dividend payout ratio of 24.04%. Management left its full-year guidance for revenue and adjusted earnings unchanged.

Analyst coverage has remained measured following the release. According to MarketBeat, the company holds a consensus rating of Hold alongside an average price objective of $253.69. While UBS Group reissued a buy rating with a $300.00 target, Needham & Company maintained a hold rating, and Citigroup assigned a neutral rating with a $270.00 price target. ResMed continues to face competitive dynamics in obstructive sleep apnea therapy, where it serves as a primary provider of positive airway pressure devices.